DK1641819T3 - Oprensning af HER-2-varianter - Google Patents
Oprensning af HER-2-varianterInfo
- Publication number
- DK1641819T3 DK1641819T3 DK04738948T DK04738948T DK1641819T3 DK 1641819 T3 DK1641819 T3 DK 1641819T3 DK 04738948 T DK04738948 T DK 04738948T DK 04738948 T DK04738948 T DK 04738948T DK 1641819 T3 DK1641819 T3 DK 1641819T3
- Authority
- DK
- Denmark
- Prior art keywords
- purification
- provides
- chromatography
- variant
- variants
- Prior art date
Links
- 238000000746 purification Methods 0.000 title abstract 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title abstract 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 238000005571 anion exchange chromatography Methods 0.000 abstract 2
- 238000001597 immobilized metal affinity chromatography Methods 0.000 abstract 2
- 238000001542 size-exclusion chromatography Methods 0.000 abstract 2
- 241000238631 Hexapoda Species 0.000 abstract 1
- 238000011026 diafiltration Methods 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48231503P | 2003-06-25 | 2003-06-25 | |
DKPA200300954 | 2003-06-25 | ||
PCT/DK2004/000451 WO2004113377A1 (en) | 2003-06-25 | 2004-06-24 | Purification of her-2 variants |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1641819T3 true DK1641819T3 (da) | 2009-08-03 |
Family
ID=33542436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04738948T DK1641819T3 (da) | 2003-06-25 | 2004-06-24 | Oprensning af HER-2-varianter |
Country Status (12)
Country | Link |
---|---|
EP (2) | EP1641819B1 (da) |
JP (1) | JP4579912B2 (da) |
AT (1) | ATE429447T1 (da) |
AU (1) | AU2004249362B2 (da) |
CA (1) | CA2530233C (da) |
DE (1) | DE602004020769D1 (da) |
DK (1) | DK1641819T3 (da) |
ES (1) | ES2325584T3 (da) |
MX (1) | MXPA05013389A (da) |
NO (1) | NO20055948L (da) |
NZ (1) | NZ544017A (da) |
WO (1) | WO2004113377A1 (da) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA008827B1 (ru) | 2003-06-25 | 2007-08-31 | Фармекса А/С | Очистка вариантов her-2 |
US20080253993A1 (en) * | 2005-03-31 | 2008-10-16 | Pharmexa A/S | Immunogenic Egfr Peptides Comprising Foreign T Cell Stimulating Epitope |
CA2665068C (en) * | 2006-10-06 | 2016-01-05 | Bn Immunotherapeutics Inc. | Methods for treating cancer with mva |
CN116438456A (zh) * | 2020-09-11 | 2023-07-14 | 格里姆普斯生物股份有限公司 | 用于疾病检测/诊断、分期、监测和治疗的离体蛋白酶活性检测 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6080409A (en) * | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
ES2222728T3 (es) | 1998-10-05 | 2005-02-01 | Pharmexa A/S | Procedimiento de vacunacion terapeutica. |
MXPA01007721A (es) * | 1999-01-29 | 2003-07-14 | Corixa Corp | Proteinas de fusion her-2/neu. |
MXPA04009809A (es) * | 2002-04-11 | 2004-12-13 | Amgen Inc | Moleculas de tirosina cinasa del receptor her-2 y uso de las mismas. |
-
2004
- 2004-06-24 AU AU2004249362A patent/AU2004249362B2/en not_active Ceased
- 2004-06-24 WO PCT/DK2004/000451 patent/WO2004113377A1/en active Application Filing
- 2004-06-24 ES ES04738948T patent/ES2325584T3/es active Active
- 2004-06-24 DK DK04738948T patent/DK1641819T3/da active
- 2004-06-24 JP JP2006515732A patent/JP4579912B2/ja not_active Expired - Fee Related
- 2004-06-24 EP EP04738948A patent/EP1641819B1/en active Active
- 2004-06-24 AT AT04738948T patent/ATE429447T1/de active
- 2004-06-24 NZ NZ544017A patent/NZ544017A/en not_active IP Right Cessation
- 2004-06-24 CA CA2530233A patent/CA2530233C/en not_active Expired - Fee Related
- 2004-06-24 DE DE602004020769T patent/DE602004020769D1/de active Active
- 2004-06-24 EP EP09005519A patent/EP2090586A1/en not_active Withdrawn
- 2004-06-24 MX MXPA05013389A patent/MXPA05013389A/es unknown
-
2005
- 2005-12-14 NO NO20055948A patent/NO20055948L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1641819B1 (en) | 2009-04-22 |
NZ544017A (en) | 2008-04-30 |
ATE429447T1 (de) | 2009-05-15 |
AU2004249362A1 (en) | 2004-12-29 |
DE602004020769D1 (de) | 2009-06-04 |
MXPA05013389A (es) | 2006-03-17 |
CA2530233A1 (en) | 2004-12-29 |
WO2004113377A1 (en) | 2004-12-29 |
ES2325584T3 (es) | 2009-09-09 |
EP1641819A1 (en) | 2006-04-05 |
CA2530233C (en) | 2012-09-11 |
AU2004249362B2 (en) | 2011-08-25 |
EP2090586A1 (en) | 2009-08-19 |
NO20055948L (no) | 2005-12-14 |
JP4579912B2 (ja) | 2010-11-10 |
JP2007523615A (ja) | 2007-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20071432L (no) | Fremgangsmate for konsentrasjon av antistoffer of terapeutiske produkter derav. | |
WO2003062375A3 (en) | Stabilizing polypeptides which have been exposed to urea | |
AU2003215188A1 (en) | Fusion proteins of humanized g250 specific antibodies and uses thereof | |
WO2002069232A3 (en) | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity | |
EP1568710A3 (en) | Antibody purification method | |
WO2008013454A3 (en) | Immunogenic compounds and protein mimics | |
DK1780269T3 (da) | Virusrensningsmetoder | |
DE60139542D1 (de) | Methoden zur herstellung humaner monoklonaler antikörper | |
WO2006041934A3 (en) | Methods and compositions for improving recombinant protein production | |
NO20063478L (no) | Noytraliserende epitopebasert vekstfremmende vaksine | |
WO2006028936A3 (en) | Heteromultimeric molecules | |
DK1208205T3 (da) | Fremgangsmåder til frembringelse af L-aminosyrer ved hjælp af en forögelse af cellulært NADPH | |
WO2000056901A3 (en) | Linear and circular expression elements | |
WO2006053021A3 (en) | Methods for engineering polypeptide variants via somatic hypermutation and polypeptides made thereby | |
WO2007130535A3 (en) | Novel protein fusion/tag technology | |
NO20055948L (no) | Rensing av HER-2 varianter | |
EA200600102A1 (ru) | Очистка вариантов her-2 | |
WO2002077648A3 (en) | Pathogenic and commensal vaccine antigens | |
WO2002063009A8 (en) | Lp mammalian proteins; related reagents | |
WO2022133191A3 (en) | Protein compositions and methods for producing and using the same | |
WO2021158982A3 (en) | Targeted translation of rna with crispr-cas13 to enhance protein synthesis | |
EP4059952A4 (en) | NOVEL PRIMOSOME ASSEMBLY PROTEIN VARIANT, AND METHOD FOR PRODUCING L-LYSINE USING THE SAME | |
EA200501137A1 (ru) | Способ и промежуточные соединения для получения оланзапина | |
DK1444354T3 (da) | Fremgangsmåde til forbedring af effektiviteten af en enzymatisk oprensningsproces | |
ATE381576T1 (de) | Verfahren zur aufreinigung eines n-terminalen fragments des hepatozytenwachstumsfaktors |